MAPT and Alzheimer disease: The fact that the presence of abnormal astrocyte reactivity determined Aβ-triggered tau pathology in CU individuals may prove to favor the inclusion of astrocyte reactivity biomarkers in the biomarker modeling1 and biological definitions27 of AD.